Latest News for: kras

Edit

Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual ...

Nasdaq Globe Newswire 25 Mar 2025
QTX3544 is an oral, G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor currently being evaluated in a Phase 1 ...
Edit

SEBI may tweak appraisal process, delink KRAs from performance reviews

Business Line 14 Mar 2025
... its employee appraisal system by severing the link between key result areas (KRAs) and annual performance evaluations..
Edit

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Science Daily 14 Mar 2025
Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy ... .
  • 1
×